Medical composition containing ivabradine and ranolazine

A composition, the technology of ranolazine, applied in the field of medicine, can solve the problems of difficulty in obtaining satisfactory curative effect on angina pectoris, aggravated headache, reflex tachycardia, etc., and achieve the effect of improving myocardial energy utilization, relieving harm, and thoroughly curative effect

Active Publication Date: 2010-07-21
LUNAN PHARMA GROUP CORPORATION
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Clinical practice has proved that it is often difficult to achieve satisfactory results in controlling angina pectoris by using a certain type of drug alone, and a combination of drugs is often required.
In clinical practice, the combination of n

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical composition containing ivabradine and ranolazine
  • Medical composition containing ivabradine and ranolazine
  • Medical composition containing ivabradine and ranolazine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Embodiment 1 common tablet

[0015] Ivabradine Hydrochloride 3.5g

[0016] Ranolazine Dihydrochloride 35g

[0017] Microcrystalline Cellulose 160g

[0018] Lactose 80g

[0019] 10% starch slurry appropriate amount

[0020] Magnesium Stearate 1.5g

[0021] Preparation process: Weigh the prescribed amount of ivabradine hydrochloride, ranolazine dihydrochloride, microcrystalline cellulose, and lactose and mix evenly. In addition, add an appropriate amount of 10% starch slurry to the mixed powder, mix evenly, make soft material, pass through a 18-mesh nylon sieve to make wet granules, and dry at about 60°C. The moisture content of the dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

Embodiment 2

[0022] Embodiment 2 common tablet

[0023] Ivabradine Hydrochloride 1.0g

[0024] Ranolazine Dihydrochloride 65g

[0025] Starch 140g

[0026] Dextrin 20g

[0027] 50% ethanol appropriate amount

[0028] Magnesium Stearate 1.0g

[0029] Preparation process: Weigh the prescribed amount of ivabradine hydrochloride, ranolazine dihydrochloride, starch, and dextrin and mix evenly. In addition, add an appropriate amount of 50% ethanol to the mixed powder, mix evenly, make soft material, pass through a 18-mesh nylon sieve to make wet granules, and dry at about 60°C. The moisture content of the dry granules should be controlled below 1.5%. Sieve through a 20-mesh sieve, mix with magnesium stearate, and press into tablets.

Embodiment 3

[0030] Embodiment 3 Dispersible tablets

[0031]Ivabradine Hydrochloride 0.1g

[0032] Ranolazine Dihydrochloride 300g

[0033] Croscarmellose Sodium 10g

[0034] Microcrystalline Cellulose 140g

[0035] Polyvinylpyrrolidone 5.5g

[0036] 5% PVP dissolved in 60% ethanol

[0037] liquid

[0038] Micronized silica gel 5g

[0039] Preparation process: Take ivabradine hydrochloride and ranolazine dihydrochloride according to the prescription, use microcrystalline cellulose as filler, cross-linked sodium carboxymethyl cellulose and polyvinylpyrrolidone as disintegrants, 5 % PVP 60% alcohol solution is used as binder, micronized silica gel is used as flow aid, granulated in one step by fluidized bed, and then compressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medical composition containing ivabradine or pharmacologically acceptable salts and ranolazine or pharmacologically acceptable salts thereof. Proved by research, the medical composition effectively relieves myocardial ischemia and has good synergetic effect on myocardial ischemia diseases, such as angina, coronary heart disease, and the like by the combined use of the ivabradine and the ranolazine. Thus, a method for treating myocardial ischemia diseases with good effect and low adverse reaction is found. The invention finds a good solution for treating myocardial ischemia diseases clinically with poor effect at present.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition for treating myocardial ischemic diseases containing active ingredients ivabradine or a pharmaceutically acceptable salt thereof and ranolazine or a pharmaceutically acceptable salt thereof. Background technique [0002] The traditional treatment of myocardial ischemic diseases is mainly symptomatic treatment. Nitrates, adrenergic β-receptor blockers, calcium channel antagonists, etc. improve the hemodynamics of the heart and the whole body, increase myocardial energy supply, The purpose of reducing myocardial energy consumption is the main drug for the treatment of myocardial ischemia. However, there are still some patients whose symptoms cannot be well controlled after receiving sufficient above-mentioned drug treatment. With further clinical research and understanding, a new concept of treating ischemic heart disease by intervening in the metabol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/55A61K31/495A61P9/10
Inventor 赵志全赵涛
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap